English
简体中文
Total: £ 56.28
Published Date: 2025-09-18 | Pages: 93 | Tables: 98 | Medical Care
The global Next Generation Antibody Therapeutics market size was US$ 14630 million in 2024 and is forecast to a readjusted size of US$ 51550 million by 2031 with a CAGR of 20.0% during the forecast period 2025-2031.
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
The global next-generation antibody therapeutics market is expected to grow significantly over the next decade, driven by the increasing prevalence of cancer, autoimmune diseases, and infectious diseases, along with advancements in biotechnology. Oncology will remain the largest segment, but there will be strong growth in autoimmune diseases, infectious diseases, and neurological conditions.
In conclusion, technological advancements, regulatory support, and the increasing use of antibodies in combination therapies will continue to fuel the market's growth, making next-gen antibody therapeutics one of the most promising areas in biopharmaceutical innovation.Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 %.
The global Next Generation Antibody Therapeutics market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics
By Type: (Dominant Segment vs High-Margin Innovation)
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
By Application: (Core Demand Driver vs Emerging Opportunity)
Cancer
Haemophilia
Other Non-Cancer Diseases
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Roche in Europe)
- Emerging Product Trends: Antibody Drug Conjugate (ADC) adoption vs. Bispecific Antibody (BsAb) premiumization
- Demand-Side Dynamics: Cancer growth in China vs. Haemophilia potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Next Generation Antibody Therapeutics market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Bispecific Antibody (BsAb) in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Haemophilia in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Next Generation Antibody Therapeutics value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Antibody Drug Conjugate (ADC)
1.2.3 Bispecific Antibody (BsAb)
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Haemophilia
1.3.4 Other Non-Cancer Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Next Generation Antibody Therapeutics Revenue Market Share by Region (2020-2025)
2.4 Global Next Generation Antibody Therapeutics Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Next Generation Antibody Therapeutics Market Size and Prospective (2020-2031)
2.5.2 Europe Next Generation Antibody Therapeutics Market Size and Prospective (2020-2031)
2.5.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size and Prospective (2020-2031)
2.5.4 Latin America Next Generation Antibody Therapeutics Market Size and Prospective (2020-2031)
2.5.5 Middle East & Africa Next Generation Antibody Therapeutics Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2020-2025)
3.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2026-2031)
3.3 Different Types Next Generation Antibody Therapeutics Representative Players
4 Breakdown Data by Application
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2020-2025)
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Next Generation Antibody Therapeutics Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2020-2025)
5.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue
5.4 Global Next Generation Antibody Therapeutics Market Concentration Analysis
5.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2024
5.5 Global Key Players of Next Generation Antibody Therapeutics Head office and Area Served
5.6 Global Key Players of Next Generation Antibody Therapeutics, Product and Application
5.7 Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Next Generation Antibody Therapeutics Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2020-2025)
6.1.2.2 North America Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2020-2025)
6.1.3.2 North America Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Next Generation Antibody Therapeutics Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2020-2025)
6.2.2.2 Europe Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2020-2025)
6.2.3.2 Europe Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Asia-Pacific Market: Players, Segments and Downstream
6.3.1 Asia-Pacific Next Generation Antibody Therapeutics Revenue by Company (2020-2025)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2020-2025)
6.3.2.2 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2020-2025)
6.3.3.2 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
6.3.4 Asia-Pacific Market Trend and Opportunities
6.4 Latin America Market: Players, Segments and Downstream
6.4.1 Latin America Next Generation Antibody Therapeutics Revenue by Company (2020-2025)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Next Generation Antibody Therapeutics Market Size by Type (2020-2025)
6.4.2.2 Latin America Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Next Generation Antibody Therapeutics Market Size by Application (2020-2025)
6.4.3.2 Latin America Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
6.4.4 Latin America Market Trend and Opportunities
6.5 Middle East & Africa Market: Players, Segments and Downstream
6.5.1 Middle East & Africa Next Generation Antibody Therapeutics Revenue by Company (2020-2025)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2020-2025)
6.5.2.2 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2020-2025)
6.5.3.2 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
6.5.4 Middle East & Africa Market Trend and Opportunities
7 Key Players Profiles
7.1 Roche
7.1.1 Roche Company Details
7.1.2 Roche Business Overview
7.1.3 Roche Next Generation Antibody Therapeutics Introduction
7.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.1.5 Roche Recent Development
7.2 Amgen
7.2.1 Amgen Company Details
7.2.2 Amgen Business Overview
7.2.3 Amgen Next Generation Antibody Therapeutics Introduction
7.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.2.5 Amgen Recent Development
7.3 Pfizer
7.3.1 Pfizer Company Details
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Next Generation Antibody Therapeutics Introduction
7.3.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.3.5 Pfizer Recent Development
7.4 Takeda
7.4.1 Takeda Company Details
7.4.2 Takeda Business Overview
7.4.3 Takeda Next Generation Antibody Therapeutics Introduction
7.4.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.4.5 Takeda Recent Development
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Company Details
7.5.2 Daiichi Sankyo Business Overview
7.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction
7.5.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.5.5 Daiichi Sankyo Recent Development
7.6 Seagen
7.6.1 Seagen Company Details
7.6.2 Seagen Business Overview
7.6.3 Seagen Next Generation Antibody Therapeutics Introduction
7.6.4 Seagen Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.6.5 Seagen Recent Development
7.7 Astellas
7.7.1 Astellas Company Details
7.7.2 Astellas Business Overview
7.7.3 Astellas Next Generation Antibody Therapeutics Introduction
7.7.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.7.5 Astellas Recent Development
7.8 Immunomedics
7.8.1 Immunomedics Company Details
7.8.2 Immunomedics Business Overview
7.8.3 Immunomedics Next Generation Antibody Therapeutics Introduction
7.8.4 Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.8.5 Immunomedics Recent Development
7.9 GSK
7.9.1 GSK Company Details
7.9.2 GSK Business Overview
7.9.3 GSK Next Generation Antibody Therapeutics Introduction
7.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.9.5 GSK Recent Development
7.10 Immunocore
7.10.1 Immunocore Company Details
7.10.2 Immunocore Business Overview
7.10.3 Immunocore Next Generation Antibody Therapeutics Introduction
7.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.10.5 Immunocore Recent Development
7.11 ADC Therapeutics
7.11.1 ADC Therapeutics Company Details
7.11.2 ADC Therapeutics Business Overview
7.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Introduction
7.11.4 ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2020-2025)
7.11.5 ADC Therapeutics Recent Development
8 Next Generation Antibody Therapeutics Market Dynamics
8.1 Next Generation Antibody Therapeutics Industry Trends
8.2 Next Generation Antibody Therapeutics Market Drivers
8.3 Next Generation Antibody Therapeutics Market Challenges
8.4 Next Generation Antibody Therapeutics Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Next Generation Antibody Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Next Generation Antibody Therapeutics Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Next Generation Antibody Therapeutics Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Next Generation Antibody Therapeutics Revenue Share by Region (2020-2025)
Table 6. Global Next Generation Antibody Therapeutics Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Next Generation Antibody Therapeutics Revenue Share Forecast by Region (2026-2031)
Table 8. Global Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2020-2025)
Table 10. Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2020-2025)
Table 15. Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Next Generation Antibody Therapeutics Application
Table 18. Global Next Generation Antibody Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Next Generation Antibody Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2024)
Table 21. Ranking of Global Top Next Generation Antibody Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Next Generation Antibody Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Next Generation Antibody Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Next Generation Antibody Therapeutics, Product and Application
Table 25. Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Next Generation Antibody Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Next Generation Antibody Therapeutics Revenue Market Share by Company (2020-2025)
Table 29. North America Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Next Generation Antibody Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Next Generation Antibody Therapeutics Revenue Market Share by Company (2020-2025)
Table 33. Europe Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 35. Asia-Pacific Next Generation Antibody Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 36. Asia-Pacific Next Generation Antibody Therapeutics Revenue Market Share by Company (2020-2025)
Table 37. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 38. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 39. Latin America Next Generation Antibody Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 40. Latin America Next Generation Antibody Therapeutics Revenue Market Share by Company (2020-2025)
Table 41. Latin America Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 42. Latin America Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 43. Middle East & Africa Next Generation Antibody Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Next Generation Antibody Therapeutics Revenue Market Share by Company (2020-2025)
Table 45. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 47. Roche Company Details
Table 48. Roche Business Overview
Table 49. Roche Next Generation Antibody Therapeutics Product
Table 50. Roche Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Amgen Company Details
Table 53. Amgen Business Overview
Table 54. Amgen Next Generation Antibody Therapeutics Product
Table 55. Amgen Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 56. Amgen Recent Development
Table 57. Pfizer Company Details
Table 58. Pfizer Business Overview
Table 59. Pfizer Next Generation Antibody Therapeutics Product
Table 60. Pfizer Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 61. Pfizer Recent Development
Table 62. Takeda Company Details
Table 63. Takeda Business Overview
Table 64. Takeda Next Generation Antibody Therapeutics Product
Table 65. Takeda Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Takeda Recent Development
Table 67. Daiichi Sankyo Company Details
Table 68. Daiichi Sankyo Business Overview
Table 69. Daiichi Sankyo Next Generation Antibody Therapeutics Product
Table 70. Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Daiichi Sankyo Recent Development
Table 72. Seagen Company Details
Table 73. Seagen Business Overview
Table 74. Seagen Next Generation Antibody Therapeutics Product
Table 75. Seagen Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 76. Seagen Recent Development
Table 77. Astellas Company Details
Table 78. Astellas Business Overview
Table 79. Astellas Next Generation Antibody Therapeutics Product
Table 80. Astellas Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 81. Astellas Recent Development
Table 82. Immunomedics Company Details
Table 83. Immunomedics Business Overview
Table 84. Immunomedics Next Generation Antibody Therapeutics Product
Table 85. Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 86. Immunomedics Recent Development
Table 87. GSK Company Details
Table 88. GSK Business Overview
Table 89. GSK Next Generation Antibody Therapeutics Product
Table 90. GSK Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 91. GSK Recent Development
Table 92. Immunocore Company Details
Table 93. Immunocore Business Overview
Table 94. Immunocore Next Generation Antibody Therapeutics Product
Table 95. Immunocore Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 96. Immunocore Recent Development
Table 97. ADC Therapeutics Company Details
Table 98. ADC Therapeutics Business Overview
Table 99. ADC Therapeutics Next Generation Antibody Therapeutics Product
Table 100. ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2020-2025) & (US$ Million)
Table 101. ADC Therapeutics Recent Development
Table 102. Next Generation Antibody Therapeutics Market Trends
Table 103. Next Generation Antibody Therapeutics Market Drivers
Table 104. Next Generation Antibody Therapeutics Market Challenges
Table 105. Next Generation Antibody Therapeutics Market Restraints
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Next Generation Antibody Therapeutics Product Picture
Figure 2. Global Next Generation Antibody Therapeutics Market Share by Type: 2024 VS 2031
Figure 3. Antibody Drug Conjugate (ADC) Features
Figure 4. Bispecific Antibody (BsAb) Features
Figure 5. Global Next Generation Antibody Therapeutics Market Share by Application: 2024 VS 2031
Figure 6. Cancer
Figure 7. Haemophilia
Figure 8. Other Non-Cancer Diseases
Figure 9. Next Generation Antibody Therapeutics Report Years Considered
Figure 10. Global Next Generation Antibody Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 11. Global Next Generation Antibody Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Next Generation Antibody Therapeutics Revenue Market Share by Region: 2020 VS 2024
Figure 13. North America Next Generation Antibody Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. Europe Next Generation Antibody Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Asia-Pacific Next Generation Antibody Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Latin America Next Generation Antibody Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Middle East & Africa Next Generation Antibody Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Global Next Generation Antibody Therapeutics Market Share by Players in 2024
Figure 19. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Next Generation Antibody Therapeutics Revenue in 2024
Figure 21. North America Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
Figure 22. North America Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
Figure 23. Europe Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
Figure 24. Europe Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
Figure 25. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
Figure 26. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
Figure 27. Latin America Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
Figure 28. Latin America Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
Figure 29. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2020-2025)
Figure 30. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2020-2025)
Figure 31. Roche Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 32. Amgen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 33. Pfizer Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 34. Takeda Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 35. Daiichi Sankyo Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 36. Seagen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 37. Astellas Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 38. Immunomedics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 39. GSK Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 40. Immunocore Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 41. ADC Therapeutics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2020-2025)
Figure 42. Bottom-up and Top-down Approaches for This Report
Figure 43. Data Triangulation
Figure 44. Key Executives Interviewed
